Use of Rituximab, Temozolomide, and Radiation in Recurrent and Refractory Primary Central Nervous System Lymphoma in the Philippines: a Retrospective Analysis

Overview

Journal Neurooncol Adv

Publisher Oxford University Press

Date 2022 Jul 27

PMID 35892049

Authors

Julette Marie F Batara

Almira Doreen Abigail O Apor

Christianne V Mojica

Mark Willy L Mondia

Affiliations

Soon will be listed here.

Abstract

Background: Refractory disease in primary central nervous system lymphoma (PCNSL) may occur despite adequate initial treatment. There is currently no standard of care for relapsed and recurrent PCSNL. No study to date documents using a combined regimen of radiotherapy, temozolomide, and rituximab. This study aimed to present the clinical course and outcomes of patients with recurrent or refractory disease who were given a combination of radiation, temozolomide, and rituximab.

Methods: Retrospective analysis was employed to evaluate data from recurrent or refractory PCNSL patients who were treated with radiation, temozolomide, and rituximab in two tertiary hospitals in the Philippines. Baseline demographics, treatment regimen, and outcomes were analyzed.

Results: Fifteen patients with a median age of 56 years were included, 11 with refractory disease and 4 with recurrent disease. Patients with bulky disease received either whole brain radiotherapy or partial field radiotherapy with rituximab and temozolomide given during radiation and for 6 months after radiation. Overall response rate to salvage therapy was 93.3% (14/15). Median overall survival from initial diagnosis was not reached (median follow-up: 84 months). Mortality rate was 33.3% (5/15), but only 2 out of 5 mortalities were from disease progression. There were only two reported cases of mild allergic reactions to rituximab, which did not result in treatment interruption.

Conclusion: Rituximab, temozolomide, and radiotherapy can be considered as an effective and safe salvage therapy for relapsed and recurrent central nervous system lymphoma.

References

Yuan Y, Ding T, Wang S, Chen H, Mao Y, Chen T . Current and emerging therapies for primary central nervous system lymphoma. Biomark Res. 2021; 9(1):32. PMC: 8101140. DOI: 10.1186/s40364-021-00282-z. View

Farrall A, Smith J . Changing Incidence and Survival of Primary Central Nervous System Lymphoma in Australia: A 33-Year National Population-Based Study. Cancers (Basel). 2021; 13(3). PMC: 7865336. DOI: 10.3390/cancers13030403. View

Patrick ONeill B, Decker P, Tieu C, Cerhan J . The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma. Am J Hematol. 2013; 88(12):997-1000. PMC: 4020348. DOI: 10.1002/ajh.23551. View

Plotkin S, Betensky R, Hochberg F, Grossman S, Lesser G, Nabors L . Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res. 2004; 10(17):5643-6. DOI: 10.1158/1078-0432.CCR-04-0159. View

Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K . Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma.... Eur J Cancer. 2019; 117:121-130. DOI: 10.1016/j.ejca.2019.05.024. View

Khimani N, Ng A, Chen Y, Catalano P, Silver B, Mauch P . Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy. Ann Oncol. 2010; 22(4):979-984. DOI: 10.1093/annonc/mdq548. View

Reni M, Mason W, Zaja F, Perry J, Franceschi E, Bernardi D . Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer. 2004; 40(11):1682-8. DOI: 10.1016/j.ejca.2004.03.008. View

Nayak L, Abrey L, Drappatz J, Gilbert M, Reardon D, Wen P . Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma. 2012; 54(1):58-61. PMC: 4802006. DOI: 10.3109/10428194.2012.698736. View

Grommes C, DeAngelis L . Primary CNS Lymphoma. J Clin Oncol. 2017; 35(21):2410-2418. PMC: 5516483. DOI: 10.1200/JCO.2017.72.7602. View

10.

Holdhoff M, Wagner-Johnston N, Roschewski M . Systemic Approach to Recurrent Primary CNS Lymphoma: Perspective on Current and Emerging Treatment Strategies. Onco Targets Ther. 2020; 13:8323-8335. PMC: 7445492. DOI: 10.2147/OTT.S192379. View

11.

Alnahhas I, Alsawas M, Rayi A, Palmer J, Raval R, Ong S . Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis. Neurooncol Adv. 2020; 2(1):vdaa082. PMC: 7596890. DOI: 10.1093/noajnl/vdaa082. View

12.

Chamoun K, Choquet S, Boyle E, Houillier C, Larrieu-Ciron D, Al Jijakli A . Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series. Neurology. 2016; 88(1):101-102. DOI: 10.1212/WNL.0000000000003420. View

13.

Nguyen P, Chakravarti A, Finkelstein D, Hochberg F, Batchelor T, Loeffler J . Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol. 2005; 23(7):1507-13. DOI: 10.1200/JCO.2005.01.161. View

14.

Grommes C, Pastore A, Palaskas N, Tang S, Campos C, Schartz D . Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discov. 2017; 7(9):1018-1029. PMC: 5581705. DOI: 10.1158/2159-8290.CD-17-0613. View

15.

Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M . Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer. 2007; 96(6):864-7. PMC: 2360092. DOI: 10.1038/sj.bjc.6603660. View

16.

Batchelor T, Grossman S, Mikkelsen T, Ye X, Desideri S, Lesser G . Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011; 76(10):929-30. PMC: 3059144. DOI: 10.1212/WNL.0b013e31820f2d94. View

17.

Wong E, Tishler R, Barron L, Wu J . Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer. 2004; 101(1):139-45. DOI: 10.1002/cncr.20339. View

18.

Makino K, Nakamura H, Hide T, Kuratsu J . Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status. J Neurooncol. 2011; 106(1):155-60. DOI: 10.1007/s11060-011-0652-z. View

19.

Shin S, Jung K, Ha J, Lee S, Won Y, Yoo H . Population-based Incidence and Survival for Primary Central Nervous System Lymphoma in Korea, 1999-2009. Cancer Res Treat. 2015; 47(4):569-74. PMC: 4614227. DOI: 10.4143/crt.2014.085. View

20.

Jahnke K, Thiel E, Martus P, Herrlinger U, Weller M, Fischer L . Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol. 2006; 80(2):159-65. DOI: 10.1007/s11060-006-9165-6. View